Competing Risk Regression Models for Epidemiologic Data

被引:1008
作者
Lau, Bryan [1 ,2 ]
Cole, Stephen R. [2 ,3 ]
Gange, Stephen J. [2 ]
机构
[1] Johns Hopkins Sch Med, Dept Med, Baltimore, MD 21287 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA
基金
美国国家卫生研究院;
关键词
competing risks; epidemiologic methods; mixture model; proportional hazards; regression; survival analysis; WOMENS INTERAGENCY HIV; ACTIVE ANTIRETROVIRAL THERAPY; PROPORTIONAL HAZARDS MODEL; INJECTION-DRUG USERS; CUMULATIVE INCIDENCE; MORTALITY; FAILURE; COHORT; SUBDISTRIBUTION; PROBABILITY;
D O I
10.1093/aje/kwp107
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Competing events can preclude the event of interest from occurring in epidemiologic data and can be analyzed by using extensions of survival analysis methods. In this paper, the authors outline 3 regression approaches for estimating 2 key quantities in competing risks analysis: the cause-specific relative hazard (csRH) and the subdistribution relative hazard (sdRH). They compare and contrast the structure of the risk sets and the interpretation of parameters obtained with these methods. They also demonstrate the use of these methods with data from the Women's Interagency HIV Study established in 1993, treating time to initiation of highly active antiretroviral therapy or to clinical disease progression as competing events. In our example, women with an injection drug use history were less likely than those without a history of injection drug use to initiate therapy prior to progression to acquired immunodeficiency syndrome or death by both measures of association (csRH = 0.67, 95% confidence interval: 0.57, 0.80 and sdRH = 0.60, 95% confidence interval: 0.50, 0.71). Moreover, the relative hazards for disease progression prior to treatment were elevated (csRH = 1.71, 95% confidence interval: 1.37, 2.13 and sdRH = 2.01, 95% confidence interval: 1.62, 2.51). Methods for competing risks should be used by epidemiologists, with the choice of method guided by the scientific question.
引用
收藏
页码:244 / 256
页数:13
相关论文
共 48 条
  • [1] Andersen Per K, 2012, STAT MODELS BASED CO
  • [2] Competing risks as a multi-state model
    Andersen, PK
    Abildstrom, SZ
    Rosthoj, S
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2002, 11 (02) : 203 - 215
  • [3] [Anonymous], 2001, Classical competing risks
  • [4] Babiker A, 2002, INT J EPIDEMIOL, V31, P951, DOI 10.1093/ije/31.5.951
  • [5] The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench
    Bacon, MC
    von Wyl, V
    Alden, C
    Sharp, G
    Robison, E
    Hessol, N
    Gange, S
    Barranday, Y
    Holman, S
    Weber, K
    Young, MA
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (09) : 1013 - 1019
  • [6] The Women's Interagency HIV Study
    Barkan, SE
    Melnick, SL
    Preston-Martin, S
    Weber, K
    Kalish, LA
    Miotti, P
    Young, M
    Greenblatt, R
    Sacks, H
    Feldman, J
    [J]. EPIDEMIOLOGY, 1998, 9 (02) : 117 - 125
  • [7] A competing risks analysis of bloodstream infection after stem-cell transplantation using subdistribution hazards and cause-specific hazards
    Beyersmann, Jan
    Dettenkofer, Markus
    Bertz, Hartmut
    Schumacher, Martin
    [J]. STATISTICS IN MEDICINE, 2007, 26 (30) : 5360 - 5369
  • [8] Breslow N.E., 1972, J ROYAL STAT SOC B, V34, P187
  • [9] Self-reported antiretroviral therapy in injection drug users
    Celentano, DD
    Vlahov, D
    Cohn, S
    Shadle, VM
    Obasanjo, O
    Moore, RD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06): : 544 - 546
  • [10] Time to initiating highly active antiretroviral therapy among HIV infected injection drug users
    Celentano, DD
    Galai, N
    Sethi, AK
    Shah, NG
    Strathdee, SA
    Vlahov, D
    Gallant, JE
    [J]. AIDS, 2001, 15 (13) : 1707 - 1715